e-learning
resources
Glasgow 2004
Monday 06.09.2004
From airway responsiveness to perception of symptoms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Acute protective effect of inhaled fluticasone on airway hyperresponsiveness to adenosine 5’-monophosphate in asthma but not in chronic obstructive pulmonary disease
S. Lucia, S. Vincenza, P. Gaetano, D. M. Giuseppe, P. Riccardo (Catania, Italy)
Source:
Annual Congress 2004 - From airway responsiveness to perception of symptoms
Session:
From airway responsiveness to perception of symptoms
Session type:
Poster Discussion
Number:
2728
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Lucia, S. Vincenza, P. Gaetano, D. M. Giuseppe, P. Riccardo (Catania, Italy). Acute protective effect of inhaled fluticasone on airway hyperresponsiveness to adenosine 5’-monophosphate in asthma but not in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: Suppl. 48, 2728
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Rapid protective effect of inhaled fluticasone on airway hyperresponsiveness to AMP in patients with fixed airway obstruction due to asthma but not COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 670s
Year: 2006
Characteristics of airway hyperresponsiveness and reversibility in asthma and chronic obstructive pulmonary disease
Source: Annual Congress 2008 - PG17 - An expert view of the differences between asthma and COPD
Year: 2008
Role of tissue kallikrein 1 in late phase bronchoconstriction and airway hyperresponsiveness
Source: Annual Congress 2006 - Basic mechanisms of allergic airways inflammation
Year: 2006
Dissociation in effects of fluticasone but not fluticasone/salmeterol on lung function and airway hyperresponsiveness in mild persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 385s
Year: 2002
Effects of inhaled corticosteroids on airway inflammations of different types in patients with chronic obstructive pulmonary disease or asthma in stable phase
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009
Evaluation of the effect of inhaled ciclesonide on inflammatory and allergic markers and pulmonary function in bronchial asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Effects of fluticasone and ciclesonide on pulmonary function and airway inflammation in stable mild asthmatics
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
Dose–response for inhaled fluticasone on airway and systemic inflammation in COPD
Source: Eur Respir J 2011; 37: 206-209
Year: 2011
Dose response for inhaled fluticasone on airway and systemic inflammation in COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
The role of nebulised budesonide in the treatment of exacerbations of COPD
Source: Eur Respir J 2007; 29: 660-667
Year: 2007
Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 24: Suppl. 48, 13s
Year: 2004
Inhaled budesonide in the management of chronic obstructive pulmonary diseases
Source: Eur Respir J 2002; 20: Suppl. 38, 244s
Year: 2002
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Source: Eur Respir J 2006; 27: 964-971
Year: 2006
Additive benefits of tiotropium in asthmatics and in patients with asthma complicated chronic obstructive pulmonary disease
Source: Eur Respir J 2007; 30: Suppl. 51, 546s
Year: 2007
Bronchial hyperreactivity in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: Suppl. 45, 424s
Year: 2003
Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) and COPD concomitant with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 521s
Year: 2004
Assessment of inhalation technique in patients with bronchial asthma and chronic obstructive pulmonary disease
Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Year: 2020
Bronchodilator responsiveness in patients with COPD
Source: Eur Respir J 2008; 31: 742-750
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept